

09867-02001

- 42-

8. A polynucleotide of Claim 2 wherein said polynucleotide encodes the polypeptide encoded by the cDNA of ATCC Deposit No. 75873.

9. A polynucleotide of Claim 1 having the coding sequence as shown in Figure 1.

10. A polynucleotide of Claim 1 having the coding sequence as shown in Figure 2.

11. A polynucleotide of Claim 2 having the coding sequence deposited as ATCC Deposit No. 75875.

12. A polynucleotide of Claim 2 having the coding sequence deposited as ATCC Deposit No. 75873.

13. A vector containing the DNA of Claim 2.

14. A host cell genetically engineered with the vector of Claim 13.

15. A process for producing a polypeptide comprising: expressing from the host cell of Claim 14 the polypeptide encoded by said DNA.

16. A process for producing cells capable of expressing a polypeptide comprising genetically engineering cells with the vector of Claim 13.

17. An isolated DNA hybridizable to the DNA of Claim 2 and encoding a polypeptide having ICE-LAP-3 activity.

18. An isolated DNA hybridizable to the DNA of Claim 2 and encoding a polypeptide having ICE-LAP-4 activity.

19. A polypeptide selected from the group consisting of (i) a polypeptide having the deduced amino acid sequence of Figure 1 and fragments, analogs and derivatives thereof; (ii) a polypeptide having the deduced amino acid sequence of Figure 2 and fragments, analogs and derivatives thereof; (iii) a polypeptide encoded by the cDNA of ATCC Deposit No. 75875 and fragments, analogs and derivatives of said polypeptide; and (iv) a polypeptide encoded by the cDNA of ATCC Deposit No. 75873 and fragments, analogs and derivatives of said polypeptide.

20. A polypeptide of Claim 19 wherein the polypeptide has the deduced amino acid sequence of Figure 1.

0099553-07001

21. A polypeptide of Claim 19 wherein the polypeptide has the deduced amino acid sequence of Figure 2.
22. Antibodies against the polypeptides of claim 19.
23. An antagonist against the polypeptide of claim 19.
24. A method for the treatment of a patient having need of ICE-LAP-3 comprising: administering to the patient a therapeutically effective amount of the polypeptide of claim 19.
25. A method for the treatment of a patient having need of ICE-LAP-4 comprising: administering to the patient a therapeutically effective amount of the polypeptide of claim 19.
26. A method for the treatment of a patient having need to inhibit ICE-LAP-3 comprising: administering to the patient a therapeutically effective amount of the antagonist of Claim 23.
27. A method for the treatment of a patient having need to inhibit ICE-LAP-4 comprising: administering to the patient a therapeutically effective amount of the antagonist of Claim 23.
28. The method of Claim 24 wherein said therapeutically effective amount of the polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide *in vivo*.
29. The method of Claim 25 wherein said therapeutically effective amount of the polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide *in vivo*.
30. A method for detecting abnormal cell growth or the susceptibility to abnormal cell growth in a patient comprising:
  - isolating nucleic acid sequences encoding ICE-LAP-3 or 4 from a sample derived from a patient; and
  - detecting a mutation in the nucleic acid sequences encoding ICE-LAP-3 or 4.